Earnings Releases·Oct 28, 2026, 4:10 PM ET

Viking Therapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $183.2 million ($1.55/share) for Q3 2026, widening from $90.8 million ($0.81/share) in the prior year period, driven by a 85% increase in R&D expenses to $166.8 million; revenue remained at $0.
Secured approximately $550 million in net proceeds from concurrent upsized public offerings of stock and convertible notes in September, bringing total cash, equivalents, and short-term investments to $960 million as of September 30, 2026.
Provided future outlook confirming completion of Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 in 2027, with initiation of extension studies and the Phase 3 SUNRISE oral program expected in Q1 2027.
Announced positive top-line results for Part 1 of the VK2735 maintenance dosing study showing 83–97% weight loss retention with every-other-week dosing, while advancing VK3019 Phase 1 studies and maintaining a strong cash runway to support multiple Phase 3 trials.